Floatz logo

sup19 car-t

B-Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

140 Active assets in the B-Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

sup19 car-t is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →